Wobenzym in therapy of
rheumatoid arthritis
Guseinov N.I. Wobenzym in therapy of rheumatoid arthritis.
International Journal on Immunorehabilitation 2001, Vol. 3, No. 2,
pp. 73-74.
Proceedings of the VII International Congress on
Immunorehabilitation “Allergy, Immunology and Global Network :
Insight into the New Millennium” New York, USA, April 14 – 17, 2001
By now there are no precise indication to select basic preparations
while treating rheumatoid arthritis (RA). The basic treatment of RA
is limited by the risk of adverse drug reactions. There are no
non-toxic basic preparations for this purpose except of polyenzyme
preparations.
74 patients with RA underwent ínvestigation. Group I (n=40) received
Wobenzym 30 tablets daily during the first month, then 15 tablets
daily for a long-term treatment. Group II (n=34) received Tauredon
as basic therapy in a standard way: 1 week, 10 mg/day; 2 week, 20
mg/day, 3 week, 50 mg/day, 4 week till the 20 week 50 mg/day. In
both groups, non-steroid anti-inflammatory drugs were administered
additionally as basic therapy (150-200 mg/day). Both groups were
comparatively equal in clinical-laboratory characteristics. The
influence of basic therapy on the evolution of joint syndrome was
studied in the dynamics of clinical and laboratory indicators. Our
results showed that the defínite signs of RA remission appear at the
end of the first month in t group 1 and in the group II at the 3-4
months. The dose of non-steroid anti-inflammatory drugs was reduced,
respectively. This confirms the literature data on the basic
properties of Wobenzym therapy.